Form 13-F position report

* NEUROCRINE BIOSCIENCES INC

Reported by Sarissa Capital Management LP

NBIX CUSIP 64125C109 Manager CIK 0001577524

Reported 116,533 shares, unchanged from the prior quarter.

Reported value -15.8%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 10.79% This manager · Q3 2026
Shares 116,533 Quarter-end amount reported
Reported value $16,529,041 Fair value at quarter end
Consecutive quarters held 14 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-06-30 21811590
2023-09-30 41175000
2023-12-31 61927200
2024-03-31 47779074
2024-06-30 56511195
2024-09-30 47295851
2024-12-31 42194334
2025-03-31 34188230
2025-06-30 38103049
2025-09-30 42556337
2025-12-31 42995906
2026-03-31 15352057
2026-06-30 19639889
2026-09-30 16529041

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for * NEUROCRINE BIOSCIENCES INC held by Sarissa Capital Management LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 116,533 0 (0.0%) 10.79% $16,529,041 2026-11-16
Q2 2026 Unchanged 116,533 0 (0.0%) 11.04% $19,639,889 2026-08-14
Q1 2026 Reduced 116,533 -186,618 (-61.6%) 9.74% $15,352,057 2026-05-15
Q4 2025 Unchanged 303,151 0 (0.0%) 19.29% $42,995,906 2026-02-17
Q3 2025 Unchanged 303,151 0 (0.0%) 23.59% $42,556,337 2025-11-14
Q2 2025 Reduced 303,151 -5,965 (-1.9%) 24.68% $38,103,049 2025-08-14
Q1 2025 Unchanged 309,116 0 (0.0%) 22.1% $34,188,230 2025-05-15
Q4 2024 Reduced 309,116 -101,367 (-24.7%) 13.07% $42,194,334 2025-02-14
Q3 2024 Unchanged 410,483 0 (0.0%) 11.76% $47,295,851 2024-11-14
Q2 2024 Added 410,483 +64,057 (18.5%) 9.54% $56,511,195 2024-08-14
Q1 2024 Reduced 346,426 -123,574 (-26.3%) 8.36% $47,779,074 2024-05-15
Q4 2023 Added 470,000 +104,000 (28.4%) 9.54% $61,927,200 2024-02-14
Q3 2023 Added 366,000 +134,700 (58.2%) 5.55% $41,175,000 2023-11-14
Q2 2023 New 231,300 +231,300 (0.0%) 2.17% $21,811,590 2023-08-14

Who else reported the position

877 managers reported * NEUROCRINE BIOSCIENCES INC for Q3 2026.

Managers reporting * NEUROCRINE BIOSCIENCES INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 14,856,103 +1,144,496 0.03% $2,107,189,670 9 qtrs
Dodge & Cox Reduced 5,504,578 -80,129 0.42% $780,769,344 13 qtrs
JPMorgan Chase & Co Reduced 5,292,589 -1,106,085 0.04% $733,010,216 48 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 5,060,036 +85,953 0.03% $717,715,506 3 qtrs
STATE STREET CORPORATION Added 4,807,975 +422,377 0.02% $681,963,174 54 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 4,580,803 +35,464 0.01% $649,741,098 3 qtrs
AQR CAPITAL MANAGEMENT LLC Reduced 3,062,385 -755,652 0.13% $422,547,761 35 qtrs
Vestal Point Capital LP Added 2,500,000 +620,000 9.16% $354,600,000 3 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 2,300,697 -35,200 0.44% $326,330,862 32 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 2,127,482 -11,295 0.02% $301,038,376 54 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
116,533
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.